FHIR IG analytics14,182 resources
Start Prev Rows 1600 - 1800 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.280.json | Cancer Stage IA | active | 2024-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.281.json | Cancer Stage IB | active | 2024-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.286.json | Cancer Stage IIC | active | 2024-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.291.json | Positive Result | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.292.json | Negative Result | active | 2015-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.300.json | Pathological N Stage N1C | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.332.json | Daunorubicin Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.336.json | Palonosetron Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.341.json | External Beam Radiotherapy | active | 2024-04 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.349.json | Metastatic Cancer | active | 2023-12 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.439.json | T Category | active | 2018-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.440.json | N Category | active | 2018-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.441.json | M Category | active | 2018-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.442.json | TNM Stage Group | active | 2018-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.449.json | Opioids | active | 2024-03 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.492.json | Pharmacological interventions for depression | active | 2024-05 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.535.json | Ovarian Cancer | active | 2023-05 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.536.json | Ovarian Cancer | active | 2023-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.537.json | Fallopian Tube Cancer | active | 2022-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.539.json | Fallopian Tube Cancer | active | 2022-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.541.json | Peritoneal Cancer | active | 2022-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.542.json | Peritoneal Cancer | active | 2023-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.547.json | Cancer Stage 1C | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.555.json | Gender Female | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.556.json | Gender Male | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.557.json | Pathological N Stage N3a | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.558.json | Pathological N Stage N3b | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.560.json | Rolapitant Oral | active | 2024-07 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.599.json | Obinutuzumab Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.600.json | Ofatumumab Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.602.json | Neurokinin 1 Receptor Antagonist | active | 2024-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.604.json | Serotonin Receptor Antagonist | active | 2025-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.61.json | Cetuximab Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.63.json | Panitumumab Injectable | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.81.json | Palonosetron Oral | active | 2024-12 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.88.json | Lung Cancer | active | 2015-08 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.89.json | Lung Cancer | active | 2023-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.95.json | M Stage M0 | active | 2024-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.97.json | Pathological M Stage M1 | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.98.json | Pathological M Stage M1a | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1116.99.json | Pathological M Stage M1b | active | 2024-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1125.7.json | PROMIS Depression Assessment | active | 2023-05 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.11.json | Sleep Apnea | active | 2018-05 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.13.json | Septic Shock due to C. Diff | active | 2019-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.15.json | Body Temperature | active | 2022-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.16.json | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.17.json | Abdominal Distension | active | 2019-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.18.json | Vomiting potentially due to CDI | active | 2019-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.19.json | Ileus due to infection | active | 2019-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.20.json | Clostridium difficile infection | active | 2019-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.3.json | Radiation Therapy Indicators from CPT | active | 2017-03 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.4.json | Diagnostic Radiology Surrounding Face and Sinus | active | 2017-03 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.5.json | Ear Surgery Affecting the Tympanic Membrane | active | 2017-03 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.6.json | Allergic Rhinitis Immunotherapy | active | 2017-06 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.8.json | Radiology to Head and Sinus | active | 2017-06 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1130.9.json | Immunotherapy For Allergic Rhinitis | active | 2022-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1136.63.json | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2024-07 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.1.json | C2S Alcohol Use Disorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.11.json | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.12.json | C2S Cannabis Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.13.json | C2S Cannabis Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.14.json | C2S Cannabis Use Disorders | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.15.json | C2S Cannabis Use DIsorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.16.json | C2S Cocaine Use Disorder | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.17.json | C2S Cocaine Use Disorder | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.18.json | C2S Cocaine Use Disorder | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.19.json | C2S Hallucinogens | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.2.json | C2S Alcohol Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.20.json | C2S Hallucinogens | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.21.json | C2S Hallucinogens | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.22.json | C2S Hallucinogens | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.23.json | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 | cms | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.24.json | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.25.json | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.26.json | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.27.json | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.28.json | C2S Inhalants | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.29.json | C2S Inhalants | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.3.json | C2S Alcohol Use Disorders | active | 2016-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.30.json | C2S Inhalants | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.32.json | C2S Mental Health Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.33.json | C2S Mental Health Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.34.json | C2S Mental Health Disorders | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.35.json | C2S Mental Health Disorders | active | 2016-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.36.json | C2S Mental Health Disorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.38.json | C2S Opioids | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.39.json | C2S Opioids | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.4.json | C2S Alcohol Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.40.json | C2S Opioids | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.42.json | C2S Opioids | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.43.json | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.44.json | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.45.json | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.46.json | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.47.json | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.48.json | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.49.json | C2S Sexuality and reproductive health information sensitivity | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.5.json | C2S Alcohol Use Disorders | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.51.json | C2S Tobacco Use Disorders | active | 2016-09 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.52.json | C2S Tobacco Use Disorders | active | 2016-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.53.json | C2S Tobacco Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.54.json | C2S Tobacco Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.55.json | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 | cms | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.56.json | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.58.json | C2S Sensitive Categories | active | 2016-09 | hl7 | vsac | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.59.json | C2S Opioids | active | 2016-09 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.6.json | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 | cms | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.60.json | C2S HIV/AIDS information Sensitivity | active | 2016-09 | hl7 | cpt | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.65.json | Test C2S Alcohol Use Disorders | active | 2019-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.67.json | Test C2S HIV/AIDS Information Sensitivity | active | 2019-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.7.json | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.8.json | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1142.9.json | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.10.json | Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method) | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1002.json | Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method) | active | 2023-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1012.json | S. Typhi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1016.json | S. Paratyphi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1017.json | S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method) | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1021.json | Dark Urine (SNOMED) | active | 2023-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1022.json | Acute Onset [Qualifier Value] (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1024.json | Acute Viral Hepatitis (SNOMED) | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1027.json | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM) | active | 2023-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1029.json | Listeriosis [Listeria species] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1030.json | Meningitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1032.json | Encephalitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1033.json | Encephalitis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1035.json | Indeterminate or Equivocal Lab Result Value | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1037.json | Smoking Status [Current Nonsmoker] (SNOMED) | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1040.json | Organisms (Tests by Unspecified Method) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1041.json | Organisms (Tests by Culture and Identification) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1044.json | Candida auris Infection (Tests for Candida auris by Culture and Identification Method) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1045.json | Candida auris Infection (Tests for Candida auris Nucleic Acid) | active | 2023-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1047.json | Parkinson’s disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1048.json | Parkinson’s disease (Disorders) (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1049.json | Parkinsonism [Secondary] (ICD10CM) | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1050.json | Parkinsonism [Secondary] (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1065.json | Consciousness [Decreased Level] (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1071.json | Drug Use [IV Evidence] (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1072.json | Miosis (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1076.json | Opioid Overdose and Poisoning (Tests for Opioids [Quantitative]) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1083.json | Rash [Pustular Vesicular] (SNOMED) | active | 2023-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1084.json | Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1090.json | Syphilis [Congenital] (Disorders) (SNOMED) | active | 2023-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1091.json | Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1092.json | Congenital heart disease (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1093.json | Hearing impairment (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1095.json | Microcephaly (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1096.json | Developmental delay (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1099.json | Congenital heart disease (ICD10CM) | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1100.json | Hearing impairment (ICD10CM) | active | 2023-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1104.json | Developmental delay (ICD10CM) | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1106.json | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.112.json | Tetanus (Disorders) (SNOMED) | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1130.json | Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid) | active | 2024-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1131.json | Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1138.json | Staphylococcus Aureus (Tests by Culture and Identification Method) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1139.json | VISA/VRSA (Tests for Vancomycin Resistance Gene) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1145.json | Resistant Lab Result Value | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1148.json | Tests for Vancomycin Susceptibility [Ord] | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1149.json | Proteinuria (Tests for Total Protein in 24H Urine) | active | 2024-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.115.json | Mumps (Disorders) (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1150.json | Thrombocytopenia (Tests for Platelets [#/volume] in Blood) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1156.json | Staphylococcus aureus (Organism or Substance in Lab Results) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1169.json | Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid) | active | 2023-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.117.json | Mumps (Disorders) (ICD10CM) | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1180.json | Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative]) | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1186.json | Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative]) | active | 2023-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1188.json | Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative]) | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1196.json | Anthrax (Tests for Bacillus cereus by Culture and Identification Method) | active | 2024-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1197.json | Cervical Lymphadenitis (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1207.json | CRE (Disorders) (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1212.json | Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1213.json | NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1214.json | Carbapenemase resistance mechanism (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1215.json | Tests for carbapenemase production | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1216.json | Tests for carbapenemase resistance mechanism | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1217.json | Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem] | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1218.json | Tests for carbapenem susceptibility [Ertapenem] | active | 2024-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1219.json | Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1220.json | NU_Tests for Enterobacteriaceae species by Culture and Identification Method | active | 2023-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1224.json | Therapeutic Response to Medication [Improved] | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1225.json | Altered Mental Status (SNOMED) | active | 2023-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1230.json | Eschar (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1231.json | Hypotension (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1233.json | Localized Edema (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1234.json | Localized Edema (ICD10CM) | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1237.json | Tachycardia (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1238.json | Tachycardia (ICD10CM) | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1239.json | RCKMS Conditions (SNOMED) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.124.json | Poliomyelitis (Disorders) (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1240.json | Maternal Condition Puerperium (SNOMED) | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1242.json | Non pestis Yersiniosis Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1244.json | Blastomycosis (Disorders) (SNOMED) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1246.json | Blastomycosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1249.json | Blastomycosis (Tests for Blastomyces species by Culture and Identification Method) | active | 2024-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1250.json | Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1251.json | Blastomycosis (Tests for Blastomyces species Nucleic Acid) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1252.json | Blastomycosis (Tests for Blastomyces species Antibody) | active | 2023-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1253.json | Blastomycosis (Tests for Blastomyces species Antigen) | active | 2023-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | ValueSet-2.16.840.1.113762.1.4.1146.1265.json | Fatigue (ICD10CM) | active | 2023-01 | hl7 | icd |
FHIR
FHIRsmith